Anti-psychotic drugs, also called tranquilizers or neuroleptics, are a specific type of medication that are majorly used for the treatment of schizophrenia or bipolar disorder. They are used to manage psychosis, including hallucinations, delusions, and disordered thought of paranoia, among others. Anti-psychotic drugs are effective for the treatment of psychosis in a short duration. These drugs block the dopamine receptors in the dopaminergic pathways of the brain, thereby repressing the effect of dopamine, which is directly linked to the psychotic experiences. Increasing prevalence of mental illness in turn has led to high consumption of antipsychotics. According to National Alliance of Mental Illness 2015, 1 in 5 adults suffer from mental illness, which accounts for 18.5% of the total population suffering from the mental issues. However, long-term use of these drugs may result in side effects such as metabolic syndrome and involuntary movement disorder, ultimately leading to increased mortality in geriatric population with dementia.
Increase in prevalence of mental disorders to fuel the growth of anti-psychotic drugs market
Schizophrenia is the prime cause of psychosis across the globe and patients suffering with the disorder are more likely to succumb to physical and mental illness. According to the World Health Organization (WHO), over 21 million people worldwide were affected with schizophrenia in 2016. The WHO also states that one in two people suffering from schizophrenia do not receive appropriate care for the condition. This creates an opportunity for the market players in the global anti-psychotic drugs market to develop cost-effective medications for the treatment of this disease. Furthermore, according to the National Alliance of Medical Illness in 2017, around 1.1% adults in the U.S. live with schizophrenia, while 2.6% of the population in the country suffer from bipolar disorder. On an average, 1 in 5 adults, which adds to around 43.8 million people or 18.5% of the total population in the U.S., experience some or the other kind of mental illness in a particular year. High prevalence and increasing incidence of neurological of disorders is supporting growth of the anti-psychotic drugs market.
Antipsychotic Drug Market Taxonomy:
On the basis of drug type, the global anti-psychotic drugs market is segmented into:
- First-generation Drugs (Standard / Typical Antipsychotic Agents)
- Thorazine (Chlorpromazine HCl)
- Serentil (Mesoridazine Besylate)
- Mellaril (Thioridazine HCl)
- Haldol (Haloperidol)
- Loxitane (Loxapine Succinate)
- Trilafon (Perphenazine)
- Navane (Thiothixene)
- Sordinol (Clopenthixol)
- Second-generation Drugs (Atypical Antipsychotic Agents)
- Zyprexa (Olanzapine)
- Geodon (Ziprasidone)
- Seroquel (Quetiapine)
- Risperdal (Risperidone)
- Clozaril (Clozapine)
- Invega (Paliperidone)
- Asendin (Amoxapine)
- Latuda (Lurasidone)
- Third-generation Drugs
- Abilify (Aripiprazole)
On the basis of application, the global anti-psychotic drugs market is segmented into:
- Bipolar Disorder
- Unipolar Depression
On the basis of distribution channel, the global anti-psychotic drugs market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
North America to dominate the global anti-psychotic drugs market, owing to increasing number of patients suffering from mental disorders
On the basis of geography, the global anti-psychotic drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the largest market share in the global anti-psychotic drugs market, attributable to rising prevalence of psychosis among the youth as well increase in the prevalence of schizophrenia among the geriatric population. According to the social stats of National Academy of Mental Illness in 2017, around 70% of youth in the juvenile justice systems in the U.S suffered from at least from one mental health condition, while 20% live with a serious mental illness. Asia Pacific is expected to exhibit a significant growth in the global anti-psychotic drugs market, owing to government initiatives to improve treatment offered to increasing number of people suffering from mental illness. The World Health Organization (WHO), 2016, Pilot Programs in India, Iran, and Pakistan have exhibited a feasibility in providing care to people suffering from mental disorders such as provision of essential medicines and public education to decrease the stigma and discrimination about mental illness.
Increase in drug abuse and increasing incidence of drug addiction inadvertently fueling growth of global anti-psychotic drugs market
The major driver of the global anti-psychotic drugs market is the increase in prevalence of Schizophrenia and psychotic disorders. Several other factors such as increasing incidence of drug abuse, over prescription of psychotic drugs as well as addiction to the antipsychotic drugs further augment market growth. According to the National Survey on Drug Use and Health (NSDUH), around 13.2% of the population in the U.S. (accounting for nearly 4 million people) used an illicit drug or abused a psychotherapeutic medication in 2012. However, patent expiry of major brands over the last few years has a negative effect on market growth. Moreover, the side effects of anti-psychotics leading to tardive dyskinesia, insomnia, and several other disorders are restraining growth of the global anti-psychotic drugs market.
Key players focusing on development of novel and innovative therapeutic medication to strengthen their presence in the global antipsychotic drugs market
The key players dominating the global antipsychotic drugs market are AstraZeneca, Pfizer, Inc., Eli Lily and Co., Bristol- Myers Squibb, Johnson & Johnson, GlaxoSmithKline, and Allergen. These players are involved in developing innovative drugs for treatment of psychotic diseases with reduced side effects of the drugs to increase the consumption of the product in market. Otsuka Pharmaceuticals in November 2017 received an FDA approval for the first ever antipsychotic drug treatment Abilify MyCite, which is imbued with a digital ingestion tracking system that intends to treat Schizophrenia and acute attacks of bipolar disorder.